AbbVie Q1 FY26 diluted EPS swings to USD 0.39; net revenues rise 12.4% to USD 15 billion
AbbVie, Inc.
AbbVie, Inc. ABBV | 0.00 |
- AbbVie posted Q1 net revenues of $15 billion, up 12.4%, while diluted earnings per share fell to $0.39.
- Operating earnings totaled $4 billion; gross margin rose to $10.78 billion, lifting gross margin to 72% from 70%.
- R&D expense climbed 20% to $2.47 billion, while SG&A increased 9% to $3.58 billion.
- Skyrizi net revenues rose 30.9% to $4.48 billion, while Humira net revenues dropped 38.6% to $688 million.
- Board declared quarterly dividend of $1.73 per share beginning with dividend payable May 15, 2026; AbbVie repurchased 5 million shares for $1.1 billion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001551152-26-000017), on May 08, 2026, and is solely responsible for the information contained therein.
